CYTK
CYTOKINETICS INC
NASDAQ · Healthcare · Biotechnology · US
$62.65
+1.13%Year over year
Reported trailing growth
- Revenue
- -17.2%
- EBITDA
- -62.8%
- EBIT
- -28.8%
- EPS
- -41.1%
- Free cash flow
- -31.8%
- Operating cash flow
- -30.1%
Forward estimates
Based on analyst estimates
- Revenue
- +389.7%
- EBITDA
- +30.4%
- EPS
- +23.5%
Three-year CAGR
- Revenue
- -2.4%
- EBITDA
- -57.0%
- EBIT
- -14.2%
- Net income
- -33.2%
- EPS
- -24.3%
- Free cash flow
- -33.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026